Monoclonal antibody targeting aurora-a kinase
Référence
84999-01
Mots-clés
Monoclonal antibody, Mammal aurora-A kinase, Tumor, Screening
Statut des brevets
French patent application FR0207212 filed on June 12nd, 2002 and entitled “New monoclonal antibody specific for aurora-a kinase, useful for diagnosis, prognosis and treatment of solid tumors, also for drug screening”
Inventeurs
Claude PRIGENT
Anne MARTIN
Statut commercial
Exclusive and non exclusive licences
Laboratoire
Institut de Génétique et de Développement de Rennes (IGDR), UMR 6061, in Rennes, France, http://www.umr6061.univ-rennes1.fr/
Description
CONTEXT
The objective of this invention is to provide a reliable anti-aurora A monoclonal antibody, which links with this oncogene protein with a sufficient specificity and sensitivity, in order to envisage its use for experimental research, as well as in fields of diagnosis, prognosis and treatment of cancers.
TECHNICAL DESCRIPTION
The present invention concerns monoclonal antibody which targets the mammal aurora-A kinase (human and mouse). As the overexpression of aurora-A kinase has been observed in many tumors, it is very important to assess its expression.
Mice were injected with human recombinant aurora-A kinase and then sacrificed. Spleen cells were extracted and fused with immortalized hamster cells to obtain hybridoma. After many screening stages, an hybridoma was isolated to produce an antibody with a high affinity for the aurora-A kinase.
BENEFITS
Advantageously, in the context of the invention, the determination of a quantity of aurora-A protein lower than or greater than a physiological threshold determined as a function of the biological sample, shows respectively a good or a poor prognosis for the diagnosed cancer.
INDUSTRIAL APPLICATIONS
This innovation can be used as a research reagent in cancer research; as an in vitro diagnostic or prognostic method for cancers; or as a method for screening inhibitors of aurora-A kinase.
For further information, please contact us (Ref 84999-01)